Introduction: Peptide vs Non-Peptide Growth Hormone Secretagogues
The comparison between CJC-1295 and MK-677 (ibutamoren) represents one of the most fundamental questions in growth hormone research: should GH secretion be stimulated through a peptide GHRH analog or an oral non-peptide ghrelin mimetic? Both compounds increase GH and IGF-1 levels, but through different receptor systems, different administration routes, and with dramatically different side effect profiles.
CJC-1295 No DAC (also called modified GRF 1-29 or mod-GRF) is a synthetic 29-amino-acid peptide analog of growth hormone-releasing hormone (GHRH) that stimulates GH release by binding GHRH receptors on pituitary somatotroph cells. MK-677 is a non-peptide, orally active ghrelin receptor (GHS-R1a) agonist that mimics the GH-releasing and appetite-stimulating effects of ghrelin.
This comprehensive comparison examines both compounds across receptor pharmacology, GH/IGF-1 elevation profiles, side effects (particularly appetite and glucose effects), administration practicality, combinability, clinical evidence, and research applications.
Receptor Pharmacology
CJC-1295 No DAC: GHRH Receptor Agonism
CJC-1295 activates the GHRH receptor (GHRH-R) on anterior pituitary somatotroph cells. The GHRH-R is a Gs-coupled GPCR that activates adenylyl cyclase, increasing intracellular cAMP levels and activating protein kinase A (PKA). This cascade triggers GH gene transcription, GH synthesis, and GH vesicle exocytosis — the same pathway used by endogenous GHRH to initiate pulsatile GH release.
Key pharmacological features of CJC-1295 No DAC:
Modified stability: Four amino acid substitutions (Tyr1?D-Ala2, Ala8?Gln, Ala15?Ala, Met27?Leu) prevent enzymatic degradation by DPP-IV and other peptidases, extending the half-life from ~7 minutes (native GHRH) to 25-30 minutes.
Pulsatile GH pattern: CJC-1295 No DAC produces acute GH pulses (peak at 15-30 minutes, return to baseline within 2-3 hours) that closely mimic the physiological pulsatile GH secretion pattern. This pulsatility is critical — continuous GH elevation (as produced by exogenous GH injection) downregulates GH receptor sensitivity, while pulsatile release maintains receptor responsiveness.
Synergy with GHRPs: Because GHRH-R and GHS-R1a (ghrelin receptor) activate complementary signaling pathways (cAMP vs PLC/calcium), combining CJC-1295 with a GHRP like Ipamorelin produces synergistic GH release 3-5x greater than either compound alone. This is the most well-established peptide synergy in GH research.
MK-677: Ghrelin Receptor Agonism
MK-677 (ibutamoren mesylate) activates the same GHS-R1a receptor targeted by ghrelin, GHRP-2, GHRP-6, and ipamorelin. However, unlike peptide GHS-R1a agonists, MK-677 is a non-peptide small molecule with oral bioavailability — meaning it survives GI tract degradation and first-pass hepatic metabolism to reach systemic circulation after oral dosing.
Key pharmacological features of MK-677:
Oral bioavailability: MK-677 is active when taken orally, eliminating the need for injection. This is its single greatest practical advantage. The oral half-life is approximately 4-6 hours, but the GH/IGF-1 elevating effects persist for 24 hours after a single dose, enabling once-daily dosing.
Sustained GH elevation: Unlike pulsatile peptide secretagogues, MK-677 produces a more sustained elevation of GH levels with increased pulse amplitude but also elevated trough (nadir) levels. This pattern is less physiological than CJC-1295’s acute pulses and may contribute to some of MK-677’s side effects.
Ghrelin-like effects: Because GHS-R1a is the ghrelin receptor, MK-677 mimics ghrelin’s full spectrum of effects: GH release, appetite stimulation, gastric motility changes, and influence on reward circuitry. The appetite stimulation is a significant side effect for researchers not studying feeding behavior.
IGF-1 elevation: MK-677 produces sustained IGF-1 elevation of 39-89% in clinical studies (Nass et al., 2008). This sustained elevation contrasts with the pulsatile, transient IGF-1 increases seen with peptide secretagogues and may have different physiological implications.
GH and IGF-1 Elevation Profiles
CJC-1295 No DAC GH Profile
Typical response at 100 mcg SC: GH peak 5-15x baseline at 15-30 minutes. GH returns to baseline within 2-3 hours. When combined with Ipamorelin (200 mcg), GH peak increases to 10-30x baseline (synergistic). IGF-1 elevation is moderate and transient, reflecting the pulsatile GH pattern.
Teichman et al. (2006) studied CJC-1295 (with DAC, longer-acting version) and demonstrated sustained GH and IGF-1 elevation for 6-14 days from a single injection. The No DAC version produces shorter, more physiological pulses that better preserve somatostatin sensitivity and GH receptor responsiveness.
MK-677 GH/IGF-1 Profile
At the standard research dose of 25 mg/day oral: 24-hour GH mean increases by approximately 55-97% (Murphy et al., 1998). GH pulsatility is maintained but both pulse amplitude and nadir levels are elevated. IGF-1 increases by 39-89% sustained over the dosing period (Nass et al., 2008). Peak IGF-1 elevation occurs at 2-4 weeks and is maintained with continued dosing.
The sustained IGF-1 elevation from MK-677 is more pronounced than typical peptide secretagogue protocols, which may be advantageous for certain research applications (sustained anabolic environment) but also raises theoretical concerns about prolonged IGF-1 exposure.
Key Difference: Pulsatile vs Sustained
CJC-1295 No DAC produces acute GH pulses that mimic natural physiology. MK-677 produces elevated GH with higher nadir levels, creating a more sustained (less pulsatile) pattern. The physiological significance of this difference is debated but may affect: GH receptor sensitivity (pulsatility preserves it), body composition outcomes (both approaches show improvements), and side effect profiles (sustained elevation may drive more water retention and insulin resistance).
Side Effect Comparison: Where MK-677 Diverges
CJC-1295 No DAC Side Effects
CJC-1295 has a clean side effect profile when used alone:
Injection site reactions (mild, transient). Occasional facial flushing at higher doses. Mild water retention in some subjects. Transient numbness or tingling (paresthesias). No significant appetite stimulation. No glucose/insulin disruption at standard doses. No cortisol or prolactin elevation.
The side effect profile is comparable to ipamorelin — minimal and well-tolerated in research settings.
MK-677 Side Effects
MK-677’s side effect profile is significantly more complex, reflecting its ghrelin-mimetic activity:
Appetite stimulation: The most commonly reported side effect. MK-677 activates the same appetite-stimulating pathways as ghrelin, often producing intense hunger, particularly in the first 2-4 weeks of use. For body composition research where caloric control is important, this appetite effect is a significant confound. Subjects on MK-677 may consume excess calories, potentially offsetting the body composition benefits of GH elevation.
Water retention/edema: More pronounced than with peptide secretagogues. MK-677 can cause significant water retention, peripheral edema, and increased blood pressure. Nass et al. (2008) reported that 5/28 subjects on 25 mg MK-677 experienced edema requiring dose reduction. This is particularly relevant for elderly subjects and those with cardiovascular risk factors.
Insulin resistance and glucose elevation: MK-677 increases fasting glucose by approximately 5-10 mg/dL and increases fasting insulin, reflecting reduced insulin sensitivity. In the 2-year elderly study (Nass 2008), HbA1c increased modestly in the MK-677 group. For subjects with pre-existing insulin resistance or diabetes risk, this effect is clinically meaningful.
Cortisol elevation: MK-677 produces mild cortisol elevation (typically 10-25%), which is not seen with CJC-1295 or ipamorelin. While not dramatic, chronic cortisol elevation can contribute to insulin resistance, muscle catabolism, and immune suppression.
Lethargy/drowsiness: Some subjects report significant drowsiness with MK-677, particularly when taken during the day. This may be related to ghrelin’s role in sleep regulation — endogenous ghrelin levels naturally rise before sleep.
Joint stiffness: Common with GH elevation generally, but may be more pronounced with MK-677’s sustained GH/IGF-1 pattern.
Numbness/tingling: Carpal tunnel-like symptoms from GH-mediated water retention in tendons and nerve sheaths.
Side Effect Summary Table
| Side Effect | CJC-1295 No DAC | MK-677 |
|---|---|---|
| Appetite Increase | Minimal | Significant (ghrelin-mediated) |
| Water Retention | Mild | Moderate to significant |
| Fasting Glucose | Minimal change | Increase 5-10 mg/dL |
| Insulin Sensitivity | Preserved | Reduced |
| Cortisol | No change | Mild elevation (10-25%) |
| Prolactin | No change | No significant change |
| Drowsiness | None | Common |
| Injection Required | Yes (SC) | No (oral) |
Clinical Evidence
MK-677 Clinical Trials
MK-677 has a more extensive clinical trial record than CJC-1295, including several landmark studies:
Nass et al. (2008, Ann Intern Med): 2-year RCT in 65 healthy elderly adults (65-81 years). MK-677 25 mg/day restored GH and IGF-1 to young-adult levels. Fat-free mass increased significantly. However, fasting glucose increased, insulin sensitivity decreased, and 5 subjects developed edema requiring dose reduction or discontinuation.
Murphy et al. (1998): Demonstrated that MK-677 increased 24-hour GH secretion and IGF-1 in obese males, with sustained effects over 8 weeks. However, appetite increase and caloric intake also increased, partially offsetting body composition benefits.
Copinschi et al. (1997): Showed MK-677 increased GH pulse amplitude and IGF-1 without significantly altering GH pulse frequency, confirming its secretagogue rather than direct GH-releasing mechanism.
Despite extensive clinical research, MK-677 has NOT received FDA approval for any indication. Multiple Phase II trials have been completed, but the compound has not advanced to Phase III, potentially due to the glucose/insulin concerns and the pharmaceutical sponsor’s priorities.
CJC-1295 Clinical Evidence
CJC-1295 clinical data is more limited:
Teichman et al. (2006, JCEM): CJC-1295 (with DAC) in healthy adults showed sustained GH and IGF-1 elevation for 6-14 days from a single 30-90 mcg/kg dose. IGF-1 increased 1.5-3x above baseline. The DAC version provides longer action than the No DAC research version.
The No DAC version used in research settings has less published clinical trial data but benefits from the GHRH analog class data (sermorelin, tesamorelin) that confirms the safety and efficacy of GHRH receptor agonism. Tesamorelin (a GHRH analog like CJC-1295) is FDA-approved, providing class-level clinical validation.
Combinability: The CJC-1295 Advantage
CJC-1295’s combinability with GHRPs is a decisive advantage:
CJC-1295 + Ipamorelin: The gold-standard GH secretagogue combination. Synergistic GH release (3-5x additive) through dual-pathway activation (GHRH-R + GHS-R1a). Clean side effect profile (ipamorelin does not elevate cortisol, prolactin, or appetite). Maintains pulsatile GH pattern. This combination has become the standard GH optimization protocol in research settings.
MK-677 combination limitations: MK-677 already targets GHS-R1a — the same receptor as ipamorelin, GHRP-2, and GHRP-6. Combining MK-677 with these compounds produces redundancy, not synergy, because they compete for the same receptor. MK-677 CAN be combined with CJC-1295 (different receptors), but this combination adds MK-677’s appetite, glucose, and water retention side effects to the protocol.
The practical implication: CJC-1295 + Ipamorelin gives you the synergistic GH benefits PLUS clean selectivity. MK-677 alone gives you GH elevation PLUS appetite, glucose disruption, and water retention. And adding MK-677 to a CJC-1295 + Ipamorelin protocol adds side effects without meaningful additional GH benefit (since ipamorelin already covers GHS-R1a).
Administration: MK-677’s Practical Advantage
MK-677’s only clear advantage over CJC-1295 is oral administration. No reconstitution with bacteriostatic water, no subcutaneous injection, no refrigeration requirements. Simply take a capsule or liquid orally, once daily. For researchers or subjects who cannot tolerate injection protocols, oral administration is a meaningful practical benefit.
However, this convenience comes at the cost of the side effects detailed above. The question becomes: is oral convenience worth the appetite stimulation, glucose disruption, water retention, and cortisol elevation? For most research applications where metabolic cleanliness is important, the answer is no.
Body Composition Effects
CJC-1295 (+ Ipamorelin) body composition: GH-mediated lipolysis (fat loss through HSL activation). Modest lean mass improvement through IGF-1 elevation. No appetite confounding (subjects maintain dietary control). Preserved insulin sensitivity supports favorable glucose partitioning. Net effect: gradual but clean body composition improvement over 3-6 months.
MK-677 body composition: GH/IGF-1 elevation promotes similar lipolytic and anabolic pathways. However: appetite stimulation promotes caloric surplus ? potential fat gain. Insulin resistance promotes glucose ? fat conversion. Water retention inflates body weight and may mask true composition changes. Net effect: mixed — fat-free mass increases (documented in clinical trials) but total body composition may not improve if appetite-driven caloric excess and water retention confound the GH-mediated benefits.
Murphy et al. (1998) documented this exactly: MK-677 increased GH and IGF-1 in obese males, but caloric intake also increased, and the net fat loss was less than expected from the GH elevation alone.
Long-term Research Considerations
Tachyphylaxis: Both compounds can produce some degree of GH response attenuation with chronic use. MK-677 shows initial GH response decline over 2-4 weeks before stabilizing. CJC-1295’s pulsatile pattern better preserves somatostatin sensitivity, potentially reducing tachyphylaxis. Strategic dosing (5/2 protocols, cycling) can mitigate tachyphylaxis for both compounds.
Safety over extended periods: MK-677’s 2-year clinical data (Nass 2008) provides the longest human safety assessment for any GH secretagogue. While showing persistent efficacy, the glucose/insulin effects were chronic and did not resolve with continued dosing. CJC-1295 lacks comparable long-term clinical data, but the GHRH analog class (tesamorelin) has extended-use safety data supporting long-term tolerability.
Comparison Table
| Parameter | CJC-1295 No DAC | MK-677 |
|---|---|---|
| Type | Peptide (GHRH analog, 29 AA) | Non-peptide small molecule |
| Receptor | GHRH-R (Gs-cAMP) | GHS-R1a (Gq-PLC-Ca2+) |
| Administration | SC injection | Oral |
| GH Pattern | Pulsatile (physiological) | Sustained elevation (less physiological) |
| IGF-1 Increase | Moderate, transient | 39-89%, sustained |
| Appetite Effect | Minimal | Significant increase |
| Glucose Effect | Minimal | Increases fasting glucose/insulin |
| Cortisol | No change | Mild elevation |
| Water Retention | Mild | Moderate to significant |
| Synergy with GHRPs | Excellent (3-5x with Ipamorelin) | Redundant (same receptor as GHRPs) |
| Clinical Trials | Limited (but GHRH class = FDA-approved) | Multiple Phase II (not FDA-approved) |
| Cost | Moderate | Low to moderate |
| Storage | Refrigerated after reconstitution | Room temperature stable |
Research Applications
Choose CJC-1295 No DAC When:
Pulsatile, physiological GH stimulation is desired. Combination with Ipamorelin for synergistic GH release. Body composition research where appetite confounding must be minimized. Metabolic cleanliness is important (no glucose/insulin disruption). Long-term protocols where side effect minimization matters. Subjects with insulin resistance, diabetes risk, or metabolic concerns.
Choose MK-677 When:
Oral administration is required (injection-intolerant subjects). Sustained IGF-1 elevation is specifically desired. Appetite stimulation is a desired effect (cachexia, sarcopenia, underweight research). Cost and convenience are priorities over side effect profile. GH secretagogue mechanism studies requiring oral compound comparisons.
The Modern Research Consensus
The peptide research community has largely shifted toward CJC-1295 No DAC + Ipamorelin as the preferred GH optimization protocol, with MK-677 reserved for specific applications where oral administration or appetite stimulation is actually desired. The clean selectivity of the peptide combination (no appetite, no glucose disruption, no cortisol, synergistic GH release) consistently outperforms MK-677’s convenience advantage for the majority of research applications.
For researchers building GH optimization protocols, CJC-1295 No DAC and Ipamorelin are available from Proxiva Labs.
References
- Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295. J Clin Endocrinol Metab. 2006;91(3):799-805.
- Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008;149(9):601-611.
- Murphy MG, et al. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. J Bone Miner Res. 1999;14(suppl 1):S161.
- Copinschi G, et al. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles. J Clin Endocrinol Metab. 1997;82(6):1065-1070.
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.
- Chapman IM, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab. 1996;81(12):4249-4257.
- Smith RG, et al. A non-peptidyl growth hormone secretagogue. Science. 1993;260(5114):1640-1643.
- Howard AD, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273:974-977.
This article is for educational and research purposes only. Not intended as medical advice. All compounds discussed are for laboratory research use. Visit Proxiva Labs for verified research peptides.